Two Sigma Investments
IPHA

Two Sigma Investments’s Innate Pharma IPHA Stock Holding History

Two Sigma Investments’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,789
Closed -$38K – 2931
2022
Q3 		$38K Sell
18,789
-6,500
-26% -$17.5K ﹤0.01% 2336
2022
Q2 		$68K Sell
25,289
-10,800
-30% -$31.4K ﹤0.01% 2316
2022
Q1 		$121K Sell
36,089
-30,966
-46% -$114K ﹤0.01% 2412
2021
Q4 		$306K Buy
67,055
+48,226
+256% +$257K ﹤0.01% 3638
2021
Q3 		$116K Buy
+18,829
New +$81.1K ﹤0.01% 4066

Other funds holding IPHA

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Two Sigma Investments's IPHA Position: Q4 2022 in Review

Two Sigma Investments sold out of Innate Pharma (IPHA) in Q4 2022, closing a stake of 18,789 shares — an estimated $38K sold.

Two Sigma Investments first reported a position in IPHA in Q3 2021 and held it in 5 quarters. The position peaked at $306K in Q4 2021. 11 funds tracked by Wall St. Rank hold IPHA as of Q4 2022.

  • Two Sigma Investments reported no remaining Innate Pharma position as of Q4 2022 after selling out during the quarter.
  • Two Sigma Investments sold 18,789 Innate Pharma shares in Q4 2022, an estimated $38K.
  • Two Sigma Investments first reported a position in Innate Pharma in Q3 2021 and held it in 5 quarters.
  • Two Sigma Investments's Innate Pharma position peaked at $306K in Q4 2021.
  • 11 funds tracked by Wall St. Rank held Innate Pharma as of Q4 2022.

Based on Two Sigma Investments's 13F filing for Q4 2022, filed 14 Feb 2023.